Gnubiotics develops microbiome-centric products that target unmet needs in multiple conditions and diseases for animals and humans. The company has appointed two highly respected individuals as senior advisors to its management team with a view towards in-human clinical trials.
Gnubiotics has begun applying its innovative glycan technologies to design products which modulate the microbiome safely and effectively by selectively promoting the growth of essential commensal microbes, controlling pathogenic microbes and enhancing the production of metabolites essential for immune protection and regulating inflammatory responses. Preclinical research has begun with the goal of enhancing the efficacy of anti-cancer drugs and act as an anti-inflammatory agent when treating chronic inflammatory diseases. Gnubiotics will soon be starting preclinical trials of its first products designed for human therapeutic applications. A first product for animal health is already on the market.
The company based at Biopôle has now attracted two industry heavyweights as advisors. Prof. James Rothman, Nobel Laureate and Chairman of the Department of Cell Biology at Yale School of Medicine, and Dr. John Baldoni, former Senior Vice President of Platform Technology and Science at GSK, will bring their extensive experience and knowledge to support Gnubiotics Innovative New Drug (IND) applications for its glycopeptide assets with a view towards in-human clinical trials.
Prof. James Rothman is one of the world’s most distinguished biochemists. He was awarded the Nobel Prize in Physiology or Medicine in 2013 for his work in the field of vesicle trafficking, which revolutionized our understanding of how cells are organized and how they form and secrete glycoproteins. He previously served as Vice Chairman of the Sloan-Kettering Institute for Cancer Research, as Chief Science Officer of GE Healthcare, and as senior advisor to R&D leadership at several biopharma companies, most recently GSK and Eli Lilly.
John Baldoni is a renowned drug discovery and development expert, with extensive experience in all aspects of drug development, from basic research to scale up and market authorization. He served as the Senior Vice President of Platform Technology and Science on GSK’s R&D Executive Team. He also headed an innovative AI-drive drug discovery unit. Mr. Baldoni brings a wealth of knowledge and experience to Gnubiotics, and his expertise will be invaluable in helping the company achieve its goals.
(Press release / SK)
Picture: Fotolia / TL Furrer
Please login or sign up to comment.
Commenting guidelines